Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

  • STATUS
    Recruiting
  • participants needed
    32
  • sponsor
    Bay Area Retina Associates
Updated on 24 November 2020
Investigator
Caesar Luo, MD
Primary Contact
Bay Area Retina Associates (2.2 mi away) Contact
diabetes
cataract
vegf
growth factor
bevacizumab
ranibizumab
macular edema
aflibercept
optical coherence tomography
spectral domain optical coherence tomography
phacoemulsification
ozurdex

Summary

The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.

Description

In patients with pre-existing diabetic macular edema, anti-vascular endothelial growth factor therapy (Bevacizumab, ranibizumab, or aflibercept) will be compared to Ozurdex therapy administered 1 week prior to phacoemulsification cataract extraction. Spectral domain optical coherence tomography and visual acuity will be acquired at 1 week, 1 month, 2 months, and 3 months following cataract surgery.

Details
Treatment bevacizumab, Aflibercept, ranibizumab, Ozurdex
Clinical Study IdentifierNCT03832179
SponsorBay Area Retina Associates
Last Modified on24 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet